Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 9.81B | 9.81B | 8.38B | 5.59B | 4.81B | 2.61B |
Gross Profit | 5.67B | 5.67B | 4.69B | 3.14B | 3.05B | 1.66B |
EBITDA | -1.75B | -1.75B | 67.00M | 359.00M | 91.37M | -441.13M |
Net Income | -2.58B | -2.58B | -610.00M | -141.00M | -137.00M | -592.69M |
Balance Sheet | ||||||
Total Assets | 7.02B | 7.02B | 9.93B | 7.94B | 7.87B | 3.69B |
Cash, Cash Equivalents and Short-Term Investments | 3.01B | 3.01B | 3.49B | 5.23B | 5.54B | 2.34B |
Total Debt | 2.55B | 2.55B | 2.85B | 310.00M | 345.00M | 815.00M |
Total Liabilities | 4.48B | 4.48B | 4.95B | 1.32B | 1.23B | 1.30B |
Stockholders Equity | 2.46B | 2.46B | 4.93B | 6.54B | 6.59B | 2.38B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 505.00M | -1.12B | -843.00M | -445.00M | -1.09B |
Operating Cash Flow | 0.00 | 621.00M | -197.00M | 71.00M | 24.00M | -528.13M |
Investing Cash Flow | 0.00 | -880.00M | -2.95B | -483.00M | -701.00M | -572.57M |
Financing Cash Flow | 0.00 | -221.00M | 1.41B | 105.00M | 3.88B | 1.80B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | ¥39.25B | 18.01 | 1.74% | 12.63% | 45.75% | ||
76 Outperform | ¥36.16B | 35.25 | 0.43% | 43.96% | 57.76% | ||
74 Outperform | ¥22.80B | 18.15 | 2.79% | 5.96% | 11.80% | ||
74 Outperform | ¥43.37B | 43.65 | 0.42% | 28.85% | 40.37% | ||
73 Outperform | ¥33.54B | 50.84 | ― | 37.05% | -4.93% | ||
61 Neutral | $35.43B | 7.71 | -10.08% | 1.88% | 8.71% | -9.18% | |
61 Neutral | ¥44.16B | ― | ― | 10.39% | -322.87% |
ExaWizards Inc. has announced the continuation of its employee stock ownership plan (ESOP) trust, which was initially introduced in September 2023. This decision underscores the company’s commitment to enhancing employee engagement and corporate value by fostering a sense of belonging and encouraging management participation among employees. The plan aims to boost long-term motivation and morale, ultimately contributing to improved business performance and stock price appreciation.
ExaWizards Inc. announced a restructuring of its reportable segments to better align with its business growth and management changes. The AI Products Business will now include product-related operations from other segments, while the AI Platform Business and Other Service Business will merge into the AI Solution Services Business, aiming to enhance customer engagement and product development.
ExaWizards Inc. reported a significant improvement in its financial performance for the three months ended June 30, 2025, with net sales increasing by 15.9% year-on-year to ¥2,446 million. The company achieved an operating profit of ¥144 million, reversing a loss from the previous year, and improved its capital adequacy ratio to 39.8%. This financial turnaround indicates a positive trajectory for ExaWizards, potentially strengthening its position in the AI industry and offering promising implications for its stakeholders.
ExaWizards Inc. has finalized the terms for issuing stock acquisition rights to its directors and employees, as resolved in a board meeting on July 24, 2025. This decision involves the allocation of 9,600 stock acquisition rights, which translates to the issuance of 960,000 common shares, potentially impacting the company’s equity structure and employee incentives.
ExaWizards Inc. has announced the issuance of stock acquisition rights as stock options, aimed at boosting the motivation and morale of its directors and employees. These stock options are part of a strategy to achieve significant growth in consolidated net sales, targeting over 20 billion yen within five years. The issuance is designed to align with performance targets, thereby enhancing corporate and shareholder value, and will be executed without shareholder approval.
ExaWizards Inc. has announced the commercialization of ‘LocoStep,’ an AI gait analysis medical application developed by its subsidiary, ExaMD Inc. This innovative app, which allows for easy and quick measurement of motor function using a smartphone or iPad, is expected to contribute significantly to addressing the challenges of Japan’s aging population. While the app is designed to support healthcare providers in managing patients at risk of declining motor function, its impact on the company’s sales for the current fiscal year is anticipated to be minimal.
ExaWizards Inc. has announced the commercialization of a new AI-powered medical application, LocoStep, developed by its subsidiary ExaMD Inc. LocoStep is designed to measure motor function using a smartphone or iPad, addressing the growing issue of impaired motor function among Japan’s aging population. While the immediate financial impact is expected to be minimal, the application represents a significant step in leveraging AI to tackle health challenges in a super-aging society.
ExaWizards Inc. has entered into a capital and business alliance with NTT Communications Corporation to enhance AI solutions for Japanese companies. This partnership aims to develop a secure AI platform and industry-specific AI agents, leveraging NTT Com’s infrastructure and ExaWizards’ AI expertise. The alliance includes a third-party allotment of treasury shares to NTT Com, strengthening their collaboration and potentially increasing corporate and shareholder value.
ExaWizards Inc. announced a significant impairment loss of 2,372 million yen due to changes in the technological landscape, particularly the rise of generative AI, which affected the value of its software assets and subsidiary STADIUM Co., Ltd. The company’s actual financial results for the fiscal year ended March 31, 2025, fell short of forecasts due to delays in the AI Platform Business and upfront investments, despite strong performance in the AI Product Business, impacting its profitability and market positioning.
ExaWizards Inc. reported a significant increase in net sales for the fiscal year ending March 31, 2025, with a 17% rise compared to the previous year. Despite this growth, the company faced a substantial net loss, attributed to increased operating and ordinary profits. The financial results indicate a challenging period for ExaWizards, with implications for its market positioning and stakeholder confidence. The company forecasts further growth in net sales and operating profit for the next fiscal year, suggesting a strategic focus on improving financial performance.